Climb Bio CLYM Institutional Ownership

Updated Oct 11, 2026

Climb Bio, Inc. (NASDAQ:CLYM) was reported as a holding by 110 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Collectively, these holders controlled 73.97% of Climb Bio's outstanding shares in Q2 2026, up from 47.34% in Q1 2026.
• Total shares held in CLYM rose 74.45% from Q1 2026; the number of holders rose 66.67% from Q2 2025.
• Among the 110 holders of Climb Bio, 85 added to their positions, 18 reduced their stakes and 7 left their positions unchanged.
• Altogether, institutional holders owned 56.33Mn CLYM shares at the end of Q2 2026, up 24.04Mn from the prior quarter and up 6.67Mn from a year earlier.
• As of June 30, 2026, Ra Capital Management, L.P. held the largest stake in Climb Bio with 11.3Mn shares, or 14.84% of shares outstanding.
• Holders that added the most shares of Climb Bio in Q2 2026 were FMR LLC (+6.78Mn shares), UBS Group AG (+3.32Mn shares), BlackRock, Inc. (+1.95Mn shares), Braidwell LP (+1.27Mn shares) and Citadel Advisors LLC (+952.31K shares).
• Among holders that kept a stake in Climb Bio, the biggest sellers in Q2 2026 were Millennium Management LLC (-368.06K shares), Susquehanna International Group, LLP (-357.12K shares), Great Point Partners LLC (-334.13K shares), Two Sigma Investments, LP (-162.37K shares) and Verdad Advisers, LP (-98.42K shares).
• Per Business Quant data, the 10 largest holders of Climb Bio at the end of Q2 2026 were Ra Capital Management, L.P. (11.3Mn shares), FMR LLC (6.79Mn shares), UBS Group AG (3.4Mn shares), Braidwell LP (2.8Mn shares), Adage Capital Partners GP, L.L.C. (2.51Mn shares), BlackRock, Inc. (2.35Mn shares), T. Rowe Price Associates Inc (2.13Mn shares), Cormorant Asset Management, LP (2.11Mn shares), Frontier Capital Management Co LLC (1.94Mn shares) and Vanguard Capital Management LLC (1.7Mn shares).